MDxHealth SA Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $107.9M+19.8% YoYTTM through 31 Dec 2025
Net Income -$33.5MTTM through 31 Dec 2025
Free Cash Flow -$3.3MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Gross Margin | 64.5% |
| EBITDA Margin | -12.5% |
| Operating Margin | -13.4% |
| Net Margin | -31.1% |
Returns
277.2%ROE
-22.7%ROA
Balance Sheet Health
Debt / Equity-7.16x
Current Ratio1.08x
Net Debt$57.6M
Cash & Equivalents$29M
Quality Metrics
Piotroski F-Score3 / 9
FCF Margin-3.1%
Earnings-Beat Rate0.0%
Multi-Year Trend
RevenueFY2025: $107.9M
Diluted EPSFY2025: $-0.67
Dividend
No dividend
Capital Allocation
Capex Intensity1.1%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Tissue-based tests | $82M | ||
| Liquid-based and other tests | $25.9M |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.